Tong Ren Tang Technologies Co. Ltd. (TGRNF)
USD 0.69
(0.0%)
USD 0.69
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.71 Billion CNY | 23.19% |
| 2022 | 1.39 Billion CNY | 14.4% |
| 2021 | 1.21 Billion CNY | 10.4% |
| 2020 | 1.1 Billion CNY | -1.29% |
| 2019 | 1.11 Billion CNY | -9.32% |
| 2018 | 1.23 Billion CNY | -9.34% |
| 2017 | 1.35 Billion CNY | -0.08% |
| 2016 | 1.35 Billion CNY | 22.38% |
| 2015 | 1.11 Billion CNY | 22.88% |
| 2014 | 903.58 Million CNY | 9.34% |
| 2013 | 826.38 Million CNY | 9.51% |
| 2012 | 754.61 Million CNY | 28.54% |
| 2011 | 587.08 Million CNY | 17.61% |
| 2010 | 499.17 Million CNY | 26.35% |
| 2009 | 395.07 Million CNY | 15.4% |
| 2008 | 342.34 Million CNY | 10.03% |
| 2007 | 311.13 Million CNY | 9.49% |
| 2006 | 284.17 Million CNY | -10.17% |
| 2005 | 316.34 Million CNY | 4.28% |
| 2004 | 303.34 Million CNY | 7.76% |
| 2003 | 281.5 Million CNY | 33.22% |
| 2002 | 211.3 Million CNY | 23.57% |
| 2001 | 170.99 Million CNY | 75.04% |
| 2000 | 97.69 Million CNY | 21.47% |
| 1999 | 80.42 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 125.56 Million USD | 0.0% |
| 2023 FY | 1.71 Billion CNY | 23.19% |
| 2023 Q2 | 133.67 Million USD | 0.0% |
| 2023 Q4 | 111.34 Million USD | 0.0% |
| 2022 Q4 | 92.73 Million USD | 0.0% |
| 2022 Q2 | 112.67 Million USD | 0.0% |
| 2022 FY | 1.39 Billion CNY | 14.4% |
| 2021 Q2 | 102.09 Million USD | 0.0% |
| 2021 FY | 1.21 Billion CNY | 10.4% |
| 2021 Q4 | 85.54 Million USD | 0.0% |
| 2020 FY | 1.1 Billion CNY | -1.29% |
| 2020 Q4 | 85.5 Million USD | 0.0% |
| 2020 Q2 | 77.55 Million USD | 0.0% |
| 2019 Q2 | 87.84 Million USD | 0.0% |
| 2019 FY | 1.11 Billion CNY | -9.32% |
| 2019 Q4 | 77.05 Million USD | 0.0% |
| 2018 FY | 1.23 Billion CNY | -9.34% |
| 2017 FY | 1.35 Billion CNY | -0.08% |
| 2016 FY | 1.35 Billion CNY | 22.38% |
| 2015 FY | 1.11 Billion CNY | 22.88% |
| 2014 FY | 903.58 Million CNY | 9.34% |
| 2013 FY | 826.38 Million CNY | 9.51% |
| 2012 FY | 754.61 Million CNY | 28.54% |
| 2011 FY | 587.08 Million CNY | 17.61% |
| 2010 FY | 499.17 Million CNY | 26.35% |
| 2009 FY | 395.07 Million CNY | 15.4% |
| 2008 FY | 342.34 Million CNY | 10.03% |
| 2007 FY | 311.13 Million CNY | 9.49% |
| 2006 FY | 284.17 Million CNY | -10.17% |
| 2005 FY | 316.34 Million CNY | 4.28% |
| 2004 FY | 303.34 Million CNY | 7.76% |
| 2003 FY | 281.5 Million CNY | 33.22% |
| 2002 FY | 211.3 Million CNY | 23.57% |
| 2001 FY | 170.99 Million CNY | 75.04% |
| 2000 FY | 97.69 Million CNY | 21.47% |
| 1999 FY | 80.42 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AstraZeneca PLC | 29.57 Billion USD | 94.204% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.07 Billion USD | 89.958% |
| CSPC Pharmaceutical Group Limited | 2.14 Billion USD | 20.154% |
| Clarus Therapeutics Holdings, Inc. | 50.96 Million USD | -3263.333% |
| Novartis AG | 24.87 Billion USD | 93.107% |
| PT Kalbe Farma Tbk. | 11823.24 Billion USD | 99.986% |